Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Peter Singleton who wrote (4390)	5/27/1998 3:24:00 PM
From: scaram(o)uche	Read Replies (1) of 6136

Peter: I sort of loosely follow the thread. Maybe I've missed it, but there hasn't been any conversation regarding DuPont buying out Merck's share of DuPont Merck and the fact that DuPont assumes responsibility for marketing DMP 266 in the U.S. Sitting here on the target that the major underwriters are playing, a market cap of exactly $1 billion. Anyone familiar with DuPont's U.S. sales force for pharmaceuticals, and if they were previously targeting AIDS docs? Anyone have a handle on Viracept margins if production was "in-house"? As I indicated in an earlier post, we need to keep an eye out for which offers Johnson might be getting, and which he might find attractive....... the ratio to watch here is price to sales, not price to earnings. There are some strong stocks out there in pharma land.... price:book.... DD, 8.3..... AGPH, 4.5 price:sales.... DD, 2.0.... AGPH, ?? Cheers! Rick

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next